Ipilimumab/pembrolizumabGranulomatous colitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1860卷 / 1期

关键词：

D O I：

10.1007/s40278-021-97661-z

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：206 / 206

相关论文

共 50 条

[1] Ipilimumab/nivolumabPerforating colitis: case report
Reactions Weekly, 2023, 1950 (1) : 232 - 232
[2] Ipilimumab/nivolumabIschaemic colitis: case report
Reactions Weekly, 2019, 1734 (1) : 294 - 294
[3] Ipilimumab/nivolumabAutoimmune colitis: case report
Reactions Weekly, 2020, 1807 (1) : 103 - 103
[4] Ipilimumab/nivolumabHyperthyreosis and colitis: case report
Reactions Weekly, 2022, 1923 (1) : 269 - 269
[5] Ipilimumab/nivolumabRecurrent colitis: case report
Reactions Weekly, 2021, 1865 (1) : 239 - 239
[6] Ipilimumab/NivolumabAutoimmune colitis and pseudoprogression: case report
Reactions Weekly, 2025, 2045 (1) : 201 - 201
[7] Ipilimumab/nivolumabHepatitis, rash and colitis: case report
Reactions Weekly, 2019, 1741 (1) : 143 - 143
[8] Ipilimumab/pembrolizumabAutoimmune colitis and pancreatitis: case report
Reactions Weekly, 2016, 1617 (1) : 145 - 145
[9] Ipilimumab/nivolumabGrade 3 colitis: case report
Reactions Weekly, 2023, 1986 (1) : 222 - 222
[10] PembrolizumabGranulomatous panniculitis: case report
Reactions Weekly, 2021, 1838 (1) : 427 - 427

← 1 2 3 4 5 →